Personal information
Name and surname**:** CINZIA CICCACCI
Email: cinzia.ciccacci@unicamillus.org

Position
Assistant Professor (RTDb) in Medical Genetics at Saint Camillus International University of Health and Medical Sciences (UniCamillus)

Education and training
- 2001 Degree in Biological Science
- 2005 PhD in Evolutionist Biology and Ecology
- 2015 Specialty degree in Medical Genetics

National academic qualifications
- Associate Professor in Medical Genetics 06/A1 (31/03/2017)
- Associate Professor in Applied Medical Technologies 06/N1 (05/12/2014)

Research activity

The scientific activity of Dr. Cinzia Ciccacci is documented by 54 publications in peer-reviewed international journals, of which 51 indexed on pubmed, for a total IF of about 185, total citations = 760 (source: Scopus) and with h -index = 17 (Source: Scopus) and 44 communications to National and International Congresses.
This activity focused at the beginning of her academic career on the Genetics of human populations and evolutionary Genetics with particular regard to A) characterization of the variability pattern for SNS (Single Nucleotide Substitutions) MisSense and SameSense in coding sequences; B) Haplotypic variability of the CFTR (Cystic Fibrosis conductance Transmembrane Regulator) gene in various human populations.
In the last 12 years her activity has been focused on: A) the research of genetic factors contributing to the susceptibility to several multifactorial diseases, (in particular inflammatory bowel diseases, systemic lupus Erythematosus, Rheumatoid arthritis, Diabetes and its complications) by investigating the role of genetic variability in relation to the phenotypic variability of these pathologies and their different clinical manifestations and complications; B) Genetic variability in the response to drugs, both in terms of efficacy and toxicity (Pharmacogenetic/Pharmacogenomics), in particular by studying the genetic predictors of response in treatments with Nevirapine (anti-retroviral drug used in the treatment of HIV) and Warfarin (oral anticoagulant).
She has participated in several research projects (concerning the Genetics of multifactorial pathologies and Pharmacogenetics) financed by MIUR and other National and International Institutions.
She is "ad hoc" Reviewer for several Journals and Academic Editor for "Plos One" and "Journal of Immunology Research".

Pubblications:

Modiano G, Bombieri C, Ciminelli BM, Belpinati F, Giorgi S, Georges MD, Scotet V, Pompei F, **Ciccacci C**, Guittard C, Audrezet MP, Begnini A, Toepfer M, Macek M, Ferec C, Claustres M, Pignatti PF. *A large-scale study of the random variability of a coding sequence: a study on the CFTR gene.* Eur J Hum Genet. 2005 Feb;13(2):184-92. IF=4.3

Pompei F, Ciminelli BM, Bombieri C, **Ciccacci** C, Koudova M, Giorgi S, Belpinati F, Begnini A, Cerny M, Des Georges M, Claustres M, Ferec C, Macek M, Modiano G, Pignatti PF. *Haplotype block structure study of the CFTR gene. Most variants are associated with the M470 allele in several* E*uropean populations*.
Eur J Hum Genet. 2006 Jan;14(1):85-93. IF=4.3

Ciminelli BM, Bonizzato A, Bombieri C, Pompei F, Gabaldo M, **Ciccacci C**, Begnini A, Holubova A, Zorzi P, Piskackova T, Macek M Jr, Castellani C, Modiano G, Pignatti PF. *Highly preferential association of NonF508del CF mutations with the M470 allele*. J Cyst Fibros. 2007 Jan;6(1):15-22. IF=3.85

Borgiani P, Perricone C, **Ciccacci C**, Romano S, Novelli G, Biancone L, Petruzziello C, Pallone F. *Interleukin-23R Arg381Gln is associated with susceptibility to Crohn's disease but not with phenotype in an Italian population*. Gastroenterology. 2007 Sep;133(3):1049-51. IF=18.2

Borgiani P, **Ciccacci C**, Forte V, Romano S, Federici G, Novelli G. *Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians*. Pharmacogenomics. 2007 Nov;8(11):1545-1550. IF=2.7

Perricone C, Borgiani P, Romano S, **Ciccacci C**, Fusco G, Novelli G, Biancone L, Calabrese E, Pallone F. *ATG16L1 Ala197Thr is not associated with susceptibility to Crohn's disease or with phenotype in an Italian population*. Gastroenterology. 2008 Jan;134(1):368-70. IF=18.2

Novelli G, **Ciccacci C,** Borgiani P, Amati M P, Abadie E. Genetic tests and genomic biomarkers: regulation, qualification and validation. *Clinical Cases in Mineral and Bone Metabolism*. 2008; 5 (2): 149-154.

Borgiani P, **Ciccacci C**, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G. *CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population*. Pharmacogenomics. 2009; 10(2):261-6. IF=2.7

G. Novelli, P. Borgiani, C. **Ciccacci**, N. Di Daniele, G. Sirugo, M. Papaluca Amati. *Pharmacogenomics: role in medicines approval and clinical use*. Public Health Genomics 2010; 13(5):284-91 IF=1.5

Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, Doro Altan AM, Paturzo G, Bramanti P, Novelli G, Palombi L. *Nevirapine-induced hepatotoxicity and Pharmacogenetics: a retrospective study in a population of Mozambique.* Pharmacogenomics. 2010 Jan;11(1):23-31 IF=2.7

Predazzi IM, Martínez-Labarga C, Vecchione, L, Mango R**, Ciccacci C**, Amati F, Ottoni C, Crawford M, Rickards O, Romeo F, Novelli G. *Population differences in allele frequencies at the OLR1 locus may*

suggest geographic disparities in cardiovascular risk events. Ann Hum Biol. 2010 Apr;37(2):136-48. IF=1.57

Ciminelli BM, Bombieri C, **Ciccacci C**, Belpinati F, Pompei F, Maselli R, Simporé J, Pignatti PF, Modiano G. *Anthropological features of the CFTR gene: Its variability in an African population*. Ann Hum Biol. 2011 Mar; 38(2):203-9. IF=1.57

Ciccacci C, Falconi M, Paolillo N, Oteri F, Forte V, Novelli G, Desideri A, Borgiani P. C*haracterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient.* Pharmacogenetics and Genomics. 2011, 21(6):344-346. IF=2.86

C Ciccacci, N Paolillo, D Di Fusco,G Novelli and P Borgiani. *EPHX1 Polymorphisms Are Not Associated with Warfarin Response in an Italian Population.* Clin Pharmacol Ther. 2011 Jun;89(6):791 IF=7.27

Ciccacci C, Biancone L, Di Fusco D, Ranieri M, Condino G, Giardina E, Onali S, Lepre T, Pallone F, Novelli G, Borgiani P. *TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in Inflammatory Bowel Disease*. J Crohns Colitis. 2013; 7 (1):44-52. IF=6.59

Ciccacci C, Di Fusco D, Cacciotti L, Morganti R, D'Amato C, Novelli G, Sangiuolo F, Spallone V, Borgiani P. *TCF7L2 gene polymorphisms and type 2 diabetes: association with diabetic retinopathy and cardiovascular autonomic neuropathy*. Acta Diabetol. 2013; 50(5):789-99. IF=3.07

Ciccacci C, Di Fusco D, Marazzi MC, Liotta G, Palombi L, Novelli G, Borgiani P. *ABCC10 rs2125739 polymorphism and nevirapine-induced hepatotoxicity: lack of association in a population from Mozambique*. Pharmacogenet Genomics. 2013 Gen; 23(1):38-39 IF=2.86

E Danese, M Montagnana, JA Johnson, AE Rettie, CF Zambon, SA Lubitz, G Suarez-Kurtz, LH Cavallari, L Zhao, M Huang, Y Nakamura, T Mushiroda, MK Kringen, P Borgiani, **C Ciccacci**, NT Au, T Langaee, V Siguret, M-A Loriot, H Sagreiya, RB Altman, MHA Shahin, SA Scott, SI Khalifa, B Chowbay, IM Suriapranata, M Teichert, BH Stricker, M Taljaard, MR Botton, JE Zhang, M Pirmohamed, X Zhang, JF Carlquist, BD Horne, MTM Lee, V Pengo, GC Guidi, P Minuz and C Fava. *Impact of the CYP4F2 p. V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis.* Clin Pharmacol Ther. 2012 Dec;92(6):746-56 IF=7.27

Ciccacci C, Di Fusco D, Cacciotti L, Morganti R, D'Amato C, Greco C, Rufini S, Novelli G, Sangiuolo F, Spallone V, Borgiani P. *MicroRNA genetic variations: association with type 2 diabetes*. Acta Diabetol. 2013, 50 (6):867-872 IF=3.07

Davide Di Fusco, **Cinzia Ciccacci**, Sara Rufini, Vittorio Forte, Giuseppe Novelli and Paola Borgiani. *Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses*. Thromb Res. 2013 Jul;132(1):123-6. IF=2.32

Cinzia Ciccacci, Davide Di Fusco, Maria C. Marazzi, Ines Zimba, Fulvio Erba, Giuseppe Novelli, Leonardo Palombi, Paola Borgiani and Giuseppe Liotta. *Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study*. Eur J Clin Pharmacol. 2013, 69 (11): 1909-1916. IF=2.9

Carlo Perricone**, Cinzia Ciccacci**, Fulvia Ceccarelli, Davide Di Fusco, Francesca Romana Spinelli, Enrica Cipriano, Giuseppe Novelli, Guido Valesini, Fabrizio Conti and Paola Borgiani. *TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development.* Immunogenetics, 2013, 65(10):703-9. IF=2.3

G Novelli, E Abadie, **C Ciccacci**, D Di Fusco, M Papaluca Amati, P Borgiani. *Biomarkers to predict drug efficacy and safety in neurodegenerative diseases*. Eur J Neurodeg Dis, 2013, 2 (1): 69-77

Lucia Novelli, **Cinzia Ciccacci**, Paola Borgiani and Giuseppe Novelli. *Recent advances in the genetic susceptibility to Osteoarthritis*. Eur J Musculoskel Dis, 2013, 2 (1): 9-19

Paola Borgiani, Davide Di Fusco, Fulvio Erba, Maria C. Marazzi, Sandro Mancinelli, Giuseppe Novelli, Leonardo Palombi, **Cinzia Ciccacci**. *HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced SJS/TEN susceptibility in a population of Mozambique*. Eur J Clin Pharmacol 2014 Mar;70(3):275-8. IF=2.9

Livia Biancone, Emma Calabrese, Carmelina Petruzziello, Alessandra Capanna, Francesca Zorzi, Sara Onali, Giovanna Condino, Elisabetta Lolli, **Cinzia Ciccacci**, Paola Borgiani, Francesco Pallone. *A family study of asymptomatic small bowel Crohn's disease*. Dig Liver Dis. 2014 Mar;46(3):276-8. IF=2.72

Ciccacci C, Morganti R, Di Fusco D, D'Amato C, Cacciotti L, Greco C, Rufini S, Novelli G, Sangiuolo F, Marfia GA, Borgiani P, Spallone V. *Common polymorphisms in MIR146a, MIR128a and MIR27a genes contribute to neuropathy susceptibility in type 2 diabetes*. Acta Diabetol. 2014 Aug;51(4):663-71. IF=3.07

Ciccacci C, Perricone C, Ceccarelli F, Rufini S, Di Fusco D, Alessandri C, Spinelli FR, Cipriano E, Novelli G, Valesini G, Borgiani P, Conti F. *A Multilocus Genetic Study in a Cohort of Italian SLE Patients Confirms the Association with STAT4 Gene and Describes a New Association with HCP5 Gene*. PLoS One. 2014 Nov 4;9(11): e111991. IF=3.06

Ciccacci C, Rufini S, Mancinelli S, Buonomo E, Giardina E, Scarcella P, Marazzi MC, Novelli G, Palombi L, Borgiani P. *A Pharmacogenetics Study in Mozambican Patients Treated with Nevirapine: Full Resequencing of TRAF3IP2 Gene Shows a Novel Association with SJS/TEN Susceptibility*. Int J Mol Sci. 2015 Mar 12;16(3):5830-8. IF=3.23

Rufini S, **Ciccacci C**, Di Fusco D, Ruffa A, Pallone F, Novelli G, Biancone L, Borgiani P. *Autophagy and inflammatory bowel disease: Association between variants of the autophagy-related IRGM gene and susceptibility to Crohn's disease*. Dig Liver Dis. 2015 Sep;47(9):744-50. IF=2.72

Ciccacci C, Rufini S, Politi C, Novelli G, Forte V, Borgiani P. *Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes.* Thromb Res. 2015 Aug;136(2):367-70. IF=2.32

Sandro Mancinelli, Francesca Lucaroni, Paola Borgiani, **Cinzia Ciccacci**, Leonardo Palombi, Patrizia De Filippis. *Low level exposure to arsenic in drinking water: a review on action mechanism, health. effects and biomarkers*. IJSR 2015 Sept; 4 (9):191-97.

Rufini Sara, **Ciccacci Cinzia**, Politi Cristina, Giardina Emiliano, Novelli Giuseppe, Borgiani Paola. *Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): an update on pharmacogenetics studies in drug-induced severe skin reaction.* Pharmacogenomics. 2015 Nov;16(17):1989-2002. IF=2.7

Fulvia Ceccarelli, Carlo Perricone,Paola Borgiani, **Cinzia Ciccacci**, Sara Rufini, Enrica Cipriano, Cristiano Alessandri, Francesca Romana Spinelli, Antonio Sili Scavalli, Giuseppe Novelli, Guido Valesini, and Fabrizio Conti. *Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype.* Journal of Immunology Research 2015, 2015:745647. IF=2.81

Ciccacci C, Politi C, Novelli G, Borgiani P. *Advances In Exploring The Role Of Micrornas In Inflammatory Bowel Disease*. Microrna. 2016, 5(1):5-11.

Ciccacci C, Conigliaro P, Perricone C, Rufini S, Triggianese P, Politi C, Novelli G, Perricone R, Borgiani P. *Polymorphisms in STAT4, IL10, PSORS1C1, PTPN2 and MIR146A genes are differently associated with prognostic factors in Italian patients affected by Rheumatoid Arthritis.* Clin Exp Immunol. 2016, 186(2):157-163. IF=3.4

Chinello M, Scommegna S, Shardlow A, Mazzoli F, De Giovanni N, Fucci N, Borgiani P, **Ciccacci C**, Locasciulli A, Calvani M. *Cannabinoid Poisoning by Hemp Seed Oil in a Child.* Pediatr Emerg Care. 2017, 33(5):344-345. IF=1.03

Cristina Politi, **Cinzia Ciccacci**, Cinzia D'Amato, Giuseppe Novelli, Paola Borgiani, Vincenza Spallone. *Recent advances in exploring the genetic susceptibility to diabetic neuropathy*. Diabetes Res Clin Pract. 2016, 120:198-208. IF=3.64

Ciccacci C, Politi C, Biancone L, Latini A, Novelli G, Calabrese E, Borgiani P. *Polymorphisms in MIR122, MIR196A2, and MIR124A genes are associated with clinical phenotypes in Inflammatory Bowel Diseases*. Mol Diagn Ther. 2017, 21(1):107-114. IF=1.91

Ciccacci C, Perricone C, Politi C, Rufini S, Ceccarelli F, Cipriano E, Alessandri C, Latini A, Valesini G, Novelli G, Conti F, Borgiani P. *A polymorphism upstream MIR1279 gene is associated with pericarditis development in Systemic Lupus Erythematosus and contributes to definition of a genetic risk profile for this complication*. Lupus 2017, 26(8):841-848. IF=2.97

Conigliaro P, **Ciccacci C**, Politi C, Triggianese P, Rufini S, Kroegler B, Perricone C, Latini A, Novelli G, Borgiani P, Perricone R. *Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 genes are associated with the response to TNF inhibitors in patients with Rheumatoid Arthritis.* Plos One 2017, 12(1): e0169956. IF=3.06

Rufini S, **Ciccacci C**, Novelli G, Borgiani P. *Pharmacogenetics of Inflammatory Bowel Disease: a focus on Crohn's Disease*. Pharmacogenomics 2017, 18(11):1095-1114. IF=2.7

Cinzia Ciccacci, Andrea Latini, Cristina Politi, Sandro Mancinelli, Maria C. Marazzi, Giuseppe Novelli, Leonardo Palombi, Paola Borgiani. *Impact of Glutathione Transferases genes polymorphisms in Nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility.* Eur J Clin Pharm 2017, 73 (10): 1253–1259. IF=2.9

Andrea Latini, **Cinzia Ciccacci**, Giuseppe Novelli, Paola Borgiani. *Polymorphisms in miRNA genes and their involvement in autoimmune diseases susceptibility*. Immunol Res. 2017 Aug;65(4):811-827. IF=2.9

Ciccacci C, Latini A, Greco C, Politi C, D'Amato C, Lauro D, Novelli G, Borgiani P, Spallone V. *Association between a MIR499A polymorphism and diabetic neuropathy in type 2 diabetes.* J Diabetes Complications. 2018, 32 (1): 11-17. IF=2.73

Politi C, **Ciccacci C**, Novelli G, Borgiani P. *Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies*. Neuromolecular Med. 2018; 20(1):1-17 IF= 3.29

Chimenti MS, Perricone C, Novelli L, Caso F, Costa L, Bogdanos D, Conigliaro P, Triggianese P, **Ciccacci C**, Borgiani P, Perricone R. *Interaction between microbiome and host genetics in psoriatic arthritis.* Autoimmun Rev. 2018; 17(3):276-283. IF=8.96

Raffaella Cascella, Claudia Strafella, Giuliana Longo, Michele Ragazzo, Laura Manzo, Cecilia De Felici, Valeria Errichiello, Valerio Caputo, Francesco Viola, Chiara Maria Eandi, Giovanni Staurenghi, Andrea Cusumano, Silvestro Mauriello, Luigi Tonino Marsella, **Cinzia Ciccacci**, Paola Borgiani, Federica Sangiuolo, Giuseppe Novelli, Federico Ricci, and Emiliano Giardina. *Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants*. Oncotarget. 2018; 9:7812-7821. IF=5.17

Ciccacci Cinzia, Politi Cristina, Mancinelli Sandro, Ciccacci Fausto, Lucaroni Francesca, Novelli Guiseppe, Marazzi Maria Cristina, Palombi Leonardo, Borgiani Paola. *A multivariate genetic analysis confirms the rs5010528 in the HLA-C locus as a significant contributor to SJS/TEN susceptibility in Mozambique HIV population treated with Nevirapine.* Journal of Antimicrobial Chemotherapy 2018; 73 (8): 2137–2140 IF=5.07

Cinzia Ciccacci, Carlo Perricone, Cristiano Alessandri, Andrea Latini, Cristina Politi, Federica Delunardo, Marina Pierdominici, Fabrizio Conti, Giuseppe Novelli, Elena Ortona, Paola Borgiani. *Evaluation of ATG5 polymorphisms in Italian patients with Systemic Lupus Erythematosus: contribution to disease susceptibility and clinical phenotypes*. Lupus 2018; 27(9) :1464-1469 IF=2.97

Cinzia Ciccacci. *Discovering the genetic contribution to cardiovascular diseases in patients affected by autoimmune diseases*. Ann Transl Med. 2018 Nov;6 (Suppl 1):S44.

Ciccacci Cinzia, Borgiani Paola. *Pharmacogenomics in Parkinson's disease: which perspective for a personalized medicine?* Neural Regeneration Research 2019; 14(1):75-76.

Danese E, Raimondi S, Montagnana M, Tagetti A, Langaee T, Borgiani P, **Ciccacci C,** Carcas AJ, Borobia AM, Tong HY, Dávila-Fajardo C, Botton MR, Bourgeois S, Deloukas P, Caldwell MD, Burmester JK, Berg RL, Cavallari LH, Drozda K, Huang M, Zhao LZ, Cen HJ, Gonzalez-Conejero R, Roldan V, Nakamura Y, Mushiroda T, Gong IY, Kim RB, Hirai K, Itoh K, Isaza C, Beltrán L, Jiménez-Varo E, Cañadas-Garre M, Giontella A, Kringen MK, Bente Foss Haug K, Gwak HS, Lee KE, Minuz P, Lee MTM, Lubitz SA, Scott S, Mazzaccara C, Sacchetti L, Genç E, Özer M, Pathare A, Krishnamoorthy R, Paldi A, Siguret V, Loriot MA, Kutala VK, Suarez-Kurtz G, Perini J, Denny JC, Ramirez AH, Mittal B, Rathore SS, Sagreiya H, Altman R, Shahin MHA, Khalifa SI, Limdi NA, Rivers C, Shendre A, Dillon C, Suriapranata IM, Zhou HH, Tan SL, Tatarunas V, Lesauskaite V, Zhang Y, Maitland-van der Zee AH, Verhoef TI, de Boer A, Taljaard M, Zambon CF, Pengo V, Zhang JE, Pirmohamed M, Johnson JA, Fava

C. *The effect of CYP4F2, VKORC1 and CYP2C9 in influencing coumarin dose. A single patient data meta-analysis in more than 15,000 individuals*. Clin Pharmacol Ther. 2018 Dec 2. doi: 10.1002/cpt.1323

Latini A, Spallone V, D'Amato C, Novelli G, Borgiani P, **Ciccacci C**. *A common polymorphism in MIR155 gene promoter region is associated with a lower risk to develop type 2 diabetes*. Acta Diabetol. 2019 Jan 11. doi: 10.1007/s00592-018-1277-x

Serena Colafrancesco, **Cinzia Ciccacci**, Roberta Priori, Andrea Latini, Giovanna Picarelli, Francesca Arienzo, Giuseppe Novelli, Guido Valesini, Carlo Perricone, and Paola Borgiani. *STAT4, TRAF3IP2, IL10, and HCP5 Polymorphisms in Sjögren's Syndrome: Association with Disease Susceptibility and Clinical Aspects.* J Imm Res 2019

In compliance with the GDPR and the Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.